ARTICLE | Company News
Alteris Therapeutics Inc., Duke University Medical Center, Johns Hopkins University deal
February 23, 2004 8:00 AM UTC
Alteris licensed from the universities additional rights to its lead product, ALT-110. The compound is a therapeutic vaccine targeting EGFRvIII, a tumor-specific splice variant of the epidermal gro...